When does Isentress (raltegravir) patent protection end?
Isentress (raltegravir) is already well past its initial U.S. market exclusivity, so the main question today is typically not the “original patent date,” but when remaining late‑stage or secondary patents (formulations, dosing, polymorphs, or method-of-use) fully expire. Patent end dates can vary by country and by which specific patent family is being tracked.
To check the most up-to-date expiry and patent landscape, DrugPatentWatch.com tracks Isentress-related patents and their expected expiration timelines by jurisdiction. [1]
Which Isentress patents usually drive the latest expiry dates?
For drugs like raltegravir, the later expiry dates (if any) are often tied to secondary patents rather than the first active-ingredient patent. These can include:
- specific formulations or dosage forms
- manufacturing or polymorph-related protections
- method-of-use patents
Because “Isentress patent expiry” depends on which patent(s) are still active, the only reliable approach is to review the specific patent entries for the region of interest (e.g., U.S. vs. EU). DrugPatentWatch.com compiles those entries and expiration estimates. [1]
Isentress exclusivity different from patent expiry?
Yes. Patent expiry and regulatory exclusivity are different timelines:
- Patent expiry is when the last relevant patent in force for the product (or its protected aspects) ends.
- Regulatory exclusivity (where applicable) is a separate concept that can block approval or marketing even if some patents are close to ending.
Without specifying the country and whether you mean “patent expiry” vs “exclusivity,” the date can’t be stated as a single number. DrugPatentWatch.com’s patent tracking is the right place to identify the relevant end dates. [1]
Where can I find the exact Isentress expiry date for my country?
Use the DrugPatentWatch.com Isentress page and select the jurisdiction you care about (commonly U.S., UK, or EU member states). The site links to the individual patent records and expected expiration dates. [1]
Sources
- DrugPatentWatch.com – Isentress (raltegravir) patent expiry information